Poststroke Cognitive Impairment in Young Patients

被引：0

作者：

L. A. Shchepankevich ^{[1
]}

K. V. Rerikh ^{[2
]}

I. A. Gribacheva ^{[1
]}

T. F. Popova ^{[2
]}

E. V. Taneeva ^{[1
]}

N. E. Tyazhelnikov ^{[1
]}

D. V. Sokolova ^{[2
]}

A. V. Boznyakov ^{[1
]}

机构：

[1] Novosibirsk State Medical University,

[2] Russian Ministry of Health,undefined

[3] State Novosibirsk Regional Clinical Hospital,undefined

来源：

Neuroscience and Behavioral Physiology | 2025年 / 55卷 / 2期

关键词：

poststroke cognitive impairment; cognitive deficit in young people; rehabilitation; neurotrophins; Cortexin;

D O I：

10.1007/s11055-025-01779-y

中图分类号：

学科分类号：

摘要：

Objective. To evaluate the effects of treatment with Cortexin on cognitive functions and quality of life in young patients after ischemic stroke (IS). Materials and methods. We report here an open prospective observational study including 30 patients aged 18–45 years with confirmed diagnoses of IS in the carotid system receiving courses of treatment with Cortexin before and after therapy. All patients underwent examination for assessment of cognitive functions using the Montreal Cognitive Assessment Scale (MoCA) and quality of life (QoL) using the SF-36 questionnaire. Results. Neuropsychological testing initially demonstrated impairments to neurodynamic, visual-spatial, and memory functions. The mean score on the MoCA questionnaire at the beginning of the study was 25.1 ± 1.4 points. Over time, improvements were seen mainly in the functions of attention and short-term memory, as well as in certain aspects of executive functions. A statistically significant increase in MoCA questionnaire scores was achieved by the end of the second course of treatment with Cortexin, to 28.4 ± 1.3 points. Follow-up neuropsychological testing showed maintenance of the level of cognitive functioning achieved (28.0 ± 1.1 points). Initial SF-36 questionnaire test results were low, indicating that IS had adverse impact on patients’ daily lives. Low QoL indicators persisted to visit 3; a significant improvement in SF-36 scores was recorded by visit 4, and this persisted to visit 5. Conclusions. Cortexin therapy in young patients with poststroke cognitive impairment was shown to be effective, safe, and well tolerated.

引用

页码：353 / 356

页数：3